Postnatally Acquired Zika Virus Disease Among Children, United States, 2016-2017.


Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
02 01 2020
Historique:
received: 17 12 2018
accepted: 01 03 2019
pubmed: 12 3 2019
medline: 7 1 2021
entrez: 12 3 2019
Statut: ppublish

Résumé

The clinical findings among children with postnatally acquired Zika virus disease are not well characterized. We describe and compare clinical signs and symptoms for children aged <18 years. Zika virus disease cases were included if they met the national surveillance case definition, had illness onset in 2016 or 2017, resided in a participating state, and were reported to the Centers for Disease Control and Prevention. Pediatric cases were aged <18 years; congenital and perinatal infections were excluded. Pediatric cases were matched to adult cases (18‒49 years). Clinical information was compared between younger and older pediatric cases and between children and adults. A total of 141 pediatric Zika virus disease cases were identified; none experienced neurologic disease. Overall, 28 (20%) were treated in an emergency department, 1 (<1%) was hospitalized; none died. Of the 4 primary clinical signs and symptoms associated with Zika virus disease, 133 (94%) children had rash, 104 (74%) fever, 67 (48%) arthralgia, and 51 (36%) conjunctivitis. Fever, arthralgia, and myalgia were more common in older children (12‒17 years) than younger children (1‒11 years). Arthralgia, arthritis, edema, and myalgia were more common in adults compared to children. This report supports previous findings that Zika virus disease is generally mild in children. The most common symptoms are similar to other childhood infections, and clinical findings and outcomes are similar to those in adults. Healthcare providers should consider a diagnosis of Zika virus infection in children with fever, rash, arthralgia, or conjunctivitis, who reside in or have traveled to an area where Zika virus transmission is occurring.

Sections du résumé

BACKGROUND
The clinical findings among children with postnatally acquired Zika virus disease are not well characterized. We describe and compare clinical signs and symptoms for children aged <18 years.
METHODS
Zika virus disease cases were included if they met the national surveillance case definition, had illness onset in 2016 or 2017, resided in a participating state, and were reported to the Centers for Disease Control and Prevention. Pediatric cases were aged <18 years; congenital and perinatal infections were excluded. Pediatric cases were matched to adult cases (18‒49 years). Clinical information was compared between younger and older pediatric cases and between children and adults.
RESULTS
A total of 141 pediatric Zika virus disease cases were identified; none experienced neurologic disease. Overall, 28 (20%) were treated in an emergency department, 1 (<1%) was hospitalized; none died. Of the 4 primary clinical signs and symptoms associated with Zika virus disease, 133 (94%) children had rash, 104 (74%) fever, 67 (48%) arthralgia, and 51 (36%) conjunctivitis. Fever, arthralgia, and myalgia were more common in older children (12‒17 years) than younger children (1‒11 years). Arthralgia, arthritis, edema, and myalgia were more common in adults compared to children.
CONCLUSIONS
This report supports previous findings that Zika virus disease is generally mild in children. The most common symptoms are similar to other childhood infections, and clinical findings and outcomes are similar to those in adults. Healthcare providers should consider a diagnosis of Zika virus infection in children with fever, rash, arthralgia, or conjunctivitis, who reside in or have traveled to an area where Zika virus transmission is occurring.

Identifiants

pubmed: 30855072
pii: 5373555
doi: 10.1093/cid/ciz195
pmc: PMC7135923
mid: NIHMS1565205
doi:

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

227-231

Subventions

Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States

Investigateurs

Wendy Jilek (W)
Jennifer Brown (J)
Taryn Stevens (T)
Julius Tonzel (J)
Christine Scott-Waldron (C)
Sean Simonson (S)
Katherine Feldman (K)
Richard Brooks (R)
Megan Galvin (M)
Sarah Scotland (S)
Catherine Brown (C)
Kristin Garafalo (K)
Mojisola Ojo (M)
Karen Worthington (K)
Nadia Thomas (N)
Erica Jamro (E)
Jonah Long (J)
Barry Miller (B)
Sepehr Arshadmansab (S)
Kelly Broussard (K)
Nicole Evert (N)
Jim Broyhill (J)
Elena Mircoff (E)

Informations de copyright

Published by Oxford University Press for the Infectious Diseases Society of America 2019.

Références

J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
JAMA Pediatr. 2018 Jul 1;172(7):686-693
pubmed: 29813148
N Engl J Med. 2009 Jun 11;360(24):2536-43
pubmed: 19516034
Pediatrics. 2017 Dec;140(6):
pubmed: 29093135
Clin Infect Dis. 2016 Nov 1;63(9):1198-1201
pubmed: 27418575
Lancet. 2016 Apr 9;387(10027):1531-1539
pubmed: 26948433
Pediatrics. 2016 May;137(5):
pubmed: 27009036
Pediatr Rep. 2018 Jan 03;9(4):7341
pubmed: 29383222
Am J Trop Med Hyg. 1969 Nov;18(6):954-71
pubmed: 5355242
Clin Infect Dis. 2019 Mar 5;68(6):919-926
pubmed: 30184178
Paediatr Perinat Epidemiol. 2017 Nov;31(6):537-545
pubmed: 28806479
MMWR Morb Mortal Wkly Rep. 2016 Oct 07;65(39):1082-1085
pubmed: 27711041
Pediatr Infect Dis J. 2012 May;31(5):459-63
pubmed: 22301475
Neurocrit Care. 2017 Jun;26(3):457-463
pubmed: 27995511
Clin Infect Dis. 2017 May 15;64(10):1445-1448
pubmed: 28186536

Auteurs

Nicole P Lindsey (NP)

Arboviral Diseases Branch, Centers for Disease Control and Prevention, Fort Collins, Colorado.

Charsey C Porse (CC)

California Department of Public Health, Sacramento.

Emily Potts (E)

Indiana State Department of Health, Indianapolis.

Judie Hyun (J)

Maryland Department of Health, Baltimore.

Kayleigh Sandhu (K)

Massachusetts Department of Public Health, Jamaica Plain.

Elizabeth Schiffman (E)

Minnesota Department of Health, St. Paul.

Kimberly B Cervantes (KB)

New Jersey Department of Health, Trenton.

Jennifer L White (JL)

New York State Department of Health, Albany.

Krystal Mason (K)

Pennsylvania Department of Health, Harrisburg.

Kamesha Owens (K)

Texas Department of State Health Services, Austin.

Caroline Holsinger (C)

Virginia Department of Health, Richmond.

Marc Fischer (M)

Arboviral Diseases Branch, Centers for Disease Control and Prevention, Fort Collins, Colorado.

J Erin Staples (JE)

Arboviral Diseases Branch, Centers for Disease Control and Prevention, Fort Collins, Colorado.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH